TY  - EJOU
AU  - Krajnc, Gloria 
AU  - Metlika, Lara 
AU  - Potočnik, Uroš 
AU  - Gole, Boris 

TI  - Biomarkers and Underlying Pathways for Prediction of Response to Vedolizumab Therapy in Inflammatory Bowel Disease
T2  - BIOCELL

PY  - 2025
VL  - 49
IS  - 6
SN  - 1667-5746

AB  - Vedolizumab is a humanized monoclonal antibody and one of the safest biologics for the treatment of both forms of inflammatory bowel disease (IBD)-Crohn’s disease and ulcerative colitis. It targets the α4β7 integrin and blocks leukocyte trafficking to the gut. Regardless of its efficacy in many patients, non-response to vedolizumab treatment poses a significant clinical challenge. In this review, we synthesize recent findings on genomic, transcriptomic, proteomic, and cellular biomarkers of vedolizumab response, emphasizing their roles in predicting therapeutic outcomes and understanding non-responsiveness. Key insights include the identification of epigenetic and transcriptomic signatures, the involvement of Th17 and IL-6 signaling, and the role of baseline inflammatory markers like albumin. Discrepancies in findings highlight the complexity of biomarker discovery and underscore the need for standardized, multiparametric approaches to refine personalized treatment strategies. By bridging knowledge gaps in vedolizumab responsiveness, this review aims to advance biomarker-driven decision-making and improve outcomes for patients with IBD.
KW  - Inflammatory bowel disease; predictive biomarkers; anti-α4β7 integrins treatment; vedolizumab

DO  - 10.32604/biocell.2025.063486